Although the value of AVP level as a biomarker for predicting the outcome of stroke has yet to be established, experimental therapy using conivaptan, a mixed vasopressin antagonist, has been tested in stroke patients for brain edema management safely (Hedna et al., 2014). This evidence concerns the gene AVP and Stroke.